Telisotuzumab vedotin
Based on 2 publication(s) in Google Scholar
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.
For research use only. We do not sell to patients.
- Purity: 99.26%
- CAS No.: 1714088-51-3
- Molecular Weight:145000 (average)
-
Storage:
-80°C, protect from light
Publications Citing Use of MedChemExpress (MCE) Telisotuzumab vedotin
More-
In Vivo Efficacy Study
-
In Vivo Imaging
-
In Vivo Efficacy Study
Biological Activity
ABBV-399 demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1714088-51-3
-
Appearance Liquid
-
Molecular Weight 145000 (average)
-
Color Colorless to light yellow
-
SMILES
[Telisotuzumab vedotin]
-
Synonyms
ABBV-399
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. [Abstract]2026 Apr 21;7(4):102688. PMID: 41856115
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).
Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.
-
Mol Cancer Ther
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. [Abstract]2025 Oct 30. PMID: 41166693
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. [Content Brief]
[2]. Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)